Joël Ménard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4553402/publications.pdf

Version: 2024-02-01

76326 30087 11,735 99 40 103 citations h-index g-index papers 110 110 110 8958 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Trends in Worldwide Research in Hypertension Over the Period 1999–2018. Hypertension, 2020, 76, 1649-1655.	2.7	45
2	Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Hypertension, 2020, 75, 956-965.	2.7	49
3	Bibliometric analysis of research relating to hypertension reported over the period 1997–2016. Journal of Hypertension, 2019, 37, 2116-2122.	0.5	58
4	Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 462-473.	2.5	32
5	Conclusion de la séance dédiée : « Évolution de la prise en charge de l'hypertension artérielle ». Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1581-1584.	0.0	0
6	Primary Cardiovascular Disease Risk Factors Predicted by Poor Working Conditions in the GAZEL Cohort. American Journal of Epidemiology, 2017, 186, 815-823.	3.4	9
7	A Global View of the Relationships between the Main Behavioural and Clinical Cardiovascular Risk Factors in the GAZEL Prospective Cohort. PLoS ONE, 2016, 11, e0162386.	2.5	14
8	Unemployment is associated with high cardiovascular event rate and increased all-cause mortality in middle-aged socially privileged individuals. International Archives of Occupational and Environmental Health, 2015, 88, 707-716.	2.3	55
9	Clearance systems in the brain—implications for Alzheimer disease. Nature Reviews Neurology, 2015, 11, 457-470.	10.1	1,127
10	Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes. Circulation: Cardiovascular Genetics, 2015, 8, 131-140.	5.1	24
11	Deciphering the Role of Vasopressin in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3297-3303.	3.6	8
12	Multiple Ascending Dose Study With the New Renin Inhibitor VTP-27999. Hypertension, 2014, 63, 942-950.	2.7	42
13	20-Year prevalence projections for dementia and impact of preventive policy about risk factors. European Journal of Epidemiology, 2013, 28, 493-502.	5.7	54
14	Aldosterone synthase inhibition in humans. Nephrology Dialysis Transplantation, 2013, 28, 36-43.	0.7	79
15	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. Cardiovascular Drugs and Therapy, 2013, 27, 145-153.	2.6	24
16	Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Renin–Angiotensin System Blockers. Hypertension, 2013, 61, 1239-1245.	2.7	8
17	Evaluation of the agreement between guidelines and initial antihypertensive drug treatment using a national health care reimbursement database. Journal of Evaluation in Clinical Practice, 2012, 18, 623-629.	1.8	8
18	Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects. Journal of the American College of Cardiology, 2011, 58, 1958-1966.	2.8	117

#	Article	IF	Citations
19	Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension. Circulation, 2011, 124, 1945-1955.	1.6	173
20	Aldosterone Synthase Inhibition With LCI699. Hypertension, 2010, 56, 831-838.	2.7	161
21	Review: Measurement of plasma renin: a critical review of methodology. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 89-90.	1.7	6
22	Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement. Clinical Chemistry, 2009, 55, 867-877.	3.2	172
23	Prorenin Contributes to Angiotensin Peptide Formation in Transgenic Rats With Rat Prorenin Expression Targeted to the Liver. Hypertension, 2009, 54, 1248-1253.	2.7	27
24	Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 947-955.	4.5	57
25	Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2074-2079.	3.6	76
26	Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception, 2007, 75, 430-437.	1.5	52
27	Very Low Oral Doses of Vitamin B-12 Increase Serum Concentrations in Elderly Subjects with Food-Bound Vitamin B-12 Malabsorption. Journal of Nutrition, 2007, 137, 373-378.	2.9	28
28	NMR-based prediction of cardiovascular risk in diabetes. Nature Medicine, 2007, 13, 399-400.	30.7	18
29	Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 49-61.	4.7	20
30	Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. American Journal of Obstetrics and Gynecology, 2006, 195, 72-77.	1.3	45
31	Assessment of Patients' and Physicians' Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study. Diabetes Care, 2006, 29, 1331-1336.	8.6	35
32	Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation, 2004, 109, 2492-2499.	1.6	184
33	Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans. Hypertension, 2004, 43, 785-790.	2.7	38
34	Cardiovascular Prognosis of "Masked Hypertension" Detected by Blood Pressure Self-measurement in Elderly Treated Hypertensive Patients. JAMA - Journal of the American Medical Association, 2004, 291, 1342.	7.4	740
35	Serial left ventricular adaptations in world-class professional cyclists. Journal of the American College of Cardiology, 2004, 44, 144-149.	2.8	209
36	Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin Il–Renin Feedback Interruption. Journal of the American Society of Nephrology: JASN, 2004, 15, 3126-3133.	6.1	234

#	Article	IF	CITATIONS
37	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Molecular and Cellular Endocrinology, 2004, 217, 45-52.	3.2	88
38	Physiologic Consequences of Vasopeptidase Inhibition in Humans: Effect of Sodium Intake. Journal of the American Society of Nephrology: JASN, 2002, 13, 2454-2463.	6.1	20
39	Altered Renin Synthesis and Secretion in the Kidneys of Heterozygous Mice with a Null Mutation in the TGF-Î ² ₂ Gene. Nephron Experimental Nephrology, 2002, 10, 374-382.	2.2	8
40	Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. Journal of Molecular Medicine, 2002, 80, 492-498.	3.9	9
41	Angiotensin-converting enzyme inhibitors. Advances in Protein Chemistry, 2001, 56, 13-75.	4.4	48
42	Angiotensin I-Converting Enzyme And Metabolism Of The Haematological Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1066-1069.	1.9	26
43	Pharmacodynamic effects of dual neutral endopeptidase–angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clinical Pharmacology and Therapeutics, 1999, 65, 448-459.	4.7	36
44	Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, The, 1998, 351, 1755-1762.	13.7	5,398
45	Prevalence, Treatment, and Control of Hypertension in the French Population *1Data From a Survey on High Blood Pressure in General Practice, 1994. American Journal of Hypertension, 1998, 11, 759-762.	2.0	99
46	Vascular and cardiac remodeling in world class professional cyclists. American Heart Journal, 1998, 136, 818-823.	2.7	33
47	Review: Low-dose diuretics, but not high-dose diuretics and \hat{l}^2 -blockers, reduce coronary heart disease and total mortality. ACP Journal Club, 1997, 127, 36.	0.1	0
48	Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. American Journal of Cardiology, 1996, 77, 739-744.	1.6	76
49	Doppler-derived pulmonary arterial systolic pressure in patients with known systemic arterial pressures. American Journal of Cardiology, 1996, 77, 767-769.	1.6	12
50	Benefits of a computer-assisted education program for hypertensive patients compared with standard education tools. Patient Education and Counseling, 1995, 26, 343-347.	2.2	50
51	Comparison of the Angiotensin II Antagonist UP269–6 with the Angiotensin Converting Enzyme Inhibitor Enalapril in Normotensive Volunteers Challenged with Angiotensin I. Journal of Cardiovascular Pharmacology, 1995, 25, 986-993.	1.9	17
52	Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. American Journal of Hypertension, 1995, 8, 1167-1176.	2.0	29
53	Renal Proliferative and Phenotypic Changes in Rats With Two-Kidney, One-Clip Goldblatt Hypertension. American Journal of Hypertension, 1994, 7, 177-185.	2.0	80
54	ISIS: a computer-assisted education program for hypertensive patients and patients at cardiovascular risk. Patient Education and Counseling, 1994, 23, S131-S132.	2.2	0

#	Article	IF	CITATIONS
55	Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney International, 1994, 46, 421-429.	5.2	83
56	Accuracy and reproducibility of left ventricular mass measurement by subcostal M-mode echocardiography in hypertensive patients and professional bicyclists. American Journal of Cardiology, 1993, 72, 620-624.	1.6	11
57	Calcium Antagonists-ACE Inhibitors Combination Therapy. Journal of Cardiovascular Pharmacology, 1993, 21, S49-S54.	1.9	24
58	Effects of Ro 40–5967, a New Calcium Antagonist, and Enalapril on Cardiac Remodeling in Renal Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1993, 21, 544-551.	1.9	24
59	1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO/ISH Meeting Hypertension Research, 1993, 16, 149-161.	2.7	37
60	Decreased renin release and constant kallikrein secretion after injection of L-NAME in isolated perfused rat kidney. Life Sciences, 1992, 50, 987-993.	4.3	52
61	Arterial and Endocrine Effects of a Combination of an Angiotensin Converting Enzyme Inhibitor and a Vasodilator in Normotensive Healthy Volunteers. Journal of Cardiovascular Pharmacology, 1991, 18, 175-181.	1.9	6
62	Computer-assisted Techniques for Evaluation and Treatment of Hypertensive Patients. American Journal of Hypertension, 1990, 3, 156-163.	2.0	22
63	Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: A 6 month double-blind comparison. Journal of the American College of Cardiology, 1990, 16, 137-142.	2.8	49
64	Predictive Factors of the Blood Pressure Fall Induced by Intravenous Nicardipine. Journal of Cardiovascular Pharmacology, 1989, 13, 370-375.	1.9	4
65	Immunologic approaches to blockade of the renin-angiotensin system: A review. American Heart Journal, 1989, 117, 756-767.	2.7	22
66	Comparison of Increase in the Enalapril Dose and Addition of Hydrochlorothiazide as Second-Step Treatment of Hypertensive Patients Not Controlled by Enalapril Alone. Journal of Cardiovascular Pharmacology, 1989, 13, 314-319.	1.9	19
67	Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. American Journal of Cardiology, 1988, 62, 1072-1077.	1.6	42
68	Predictive Factors of the Acute and Chronic Blood Pressure Fall Induced by the Calcium Antagonist Nicardipine. Annals of the New York Academy of Sciences, 1988, 522, 625-627.	3.8	0
69	Reduced urinary kallikrein in hypertensive diabetic patients. The Journal of Diabetic Complications, 1988, 2, 88-91.	0.2	0
70	Effects of Transdermal Clonidine in Young and Elderly Patients with Mild Hypertension. Journal of Cardiovascular Pharmacology, 1987, 10, 162-167.	1.9	10
71	Treatmetn of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. American Journal of Medicine, 1987, 83, 227-235.	1.5	42
72	Efficacy and tolerance of spironolactone in essential hypertension. American Journal of Cardiology, 1987, 60, 820-825.	1.6	245

#	Article	IF	Citations
73	Effects of antihypertensive treatment in one–clip, two kidney hypertension in rats. Kidney International, 1986, 29, 1011-1020.	5. 2	71
74	Presence of Renin, Angiotensinogen, and Converting Enzyme in Human Pituitary Lactotroph Cells and Prolactin Adenomas. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 231-237.	3.6	68
75	Evaluation of the capacity of gel electrophoresis, steadystate and transient state electrofocusing to resolve native human des-angiotensin-l-angiotensinogen from angiotensinogen. Electrophoresis, 1985, 6, 201-206.	2.4	2
76	Processing of rat and human angiotensinogen precursors by microsomal membranes. Molecular and Cellular Endocrinology, 1985, 43, 31-40.	3.2	8
77	Systemic hypertension after cardiac transplantation: Effect of cyclosporine on the renin-angiotensin-aldosterone system. American Journal of Cardiology, 1985, 56, 927-931.	1.6	140
78	Effects of glucocorticoids and antiglucocorticoid on angiotensinogen production by hepatoma cells in culture. In Vitro, 1984, 20, 528-534.	1.2	29
79	Identity of angiotensinogen precursors of rat brain and liver. Nature, 1984, 308, 206-208.	27.8	133
80	Diminished number of renin-containing cells in kidney biopsy samples from hypertensive women immediately postpartum: An immunomorphologic study. Kidney International, 1984, 26, 85-87.	5.2	13
81	Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. Kidney International, 1984, 25, 411-415.	5.2	13
82	Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney International, 1983, 24, 58-65.	5.2	39
83	Abnormalities of renin-containing cells in human glomerular and vascular renal diseases. Kidney International, 1983, 23, 375-379.	5.2	35
84	Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. American Journal of Cardiology, 1982, 49, 1447-1452.	1.6	45
85	Dose Dependency of Captopril Effects in Severely Hypertensive Patients. Journal of Cardiovascular Pharmacology, 1981, 3, 1229-1235.	1.9	8
86	Synthesis and Renin Inhibitory Properties of a New Soluble Pepstatin Derivative. Journal of Cardiovascular Pharmacology, 1980, 2, 687-698.	1.9	15
87	Sodium balance and renin regulation in rats: Role of intrinsic renal mechanisms. Kidney International, 1980, 17, 607-614.	5.2	12
88	Dynamic study of antidiuretic hormone during benign mineralocorticoid and metacorticoid hypertension. European Journal of Endocrinology, 1980, 95, 444-453.	3.7	5
89	Hypertension management: The computer as a participant. American Journal of Medicine, 1980, 68, 559-567.	1.5	38
90	Value of renin measurement, saralasin test, and acebutolol treatment in hypertension. Kidney International, 1979, 15, 176-183.	5. 2	17

#	Article	IF	CITATIONS
91	Abnormal regulation of antidiuretic hormone in idiopathic edema. American Journal of Medicine, 1979, 67, 67-73.	1.5	22
92	Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. American Journal of Medicine, 1978, 64, 1005-1012.	1.5	41
93	Methodologic problems in plasma renin activity measurements. American Journal of Medicine, 1976, 61, 725-730.	1.5	23
94	Rapid identification of patients with essential hypertension sensitive to acebutolol (a new) Tj ETQq0 0 0 rgBT/C	verlock 10) Tf 50 622 Td
95	Partial Characterization of Hog Renin Purified by Affinity Chromatography. FEBS Journal, 1976, 64, 621-627.	0.2	21
96	Inhibition of Human Plasma Renin Activity by Pepstatin. Journal of Clinical Endocrinology and Metabolism, 1976, 43, 1301-1306.	3.6	19
97	Purification of Neurophysins by Affinity Chromatography. FEBS Journal, 1974, 43, 371-375.	0.2	13
98	Radioimmunoassay of urinary antidiuretic hormone in man: Stimulation–suppression tests. Kidney International, 1974, 6, 184-190.	5.2	25
99	VARIATIONS IN RENIN AND ITS SUBSTRATE AFTER BINEPHRECTOMY. Lancet, The, 1968, 291, 300.	13.7	13